Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/quote/stock/BEIGENE-LTD-26123632/news/BeiGene-China-NMPA-Approves-Tislelizumab-as-Second-or-Third-Line-Treatment-for-Patients-with-Loca-37506710/?utm_source=whatsapp&utm_medium=social&utm_campaign=share